Biomaterials market size in 2026 is estimated at USD 229.72 billion, growing from 2025 value of USD 202.37 billion with 2031 projections showing USD 433.06 billion, growing at 13.51% CAGR over 2026-2031. This report is Segmented by Material Type (Metals, Polymeric, Ceramic, Composite, Natural), Origin (Synthetic, Natural), Application (Orthopedic, Cardiovascular, Dental, Wound Healing, Neurology, Plastic Surgery, Tissue Engineering & Regeneration, Others), and Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa). The Market Forecasts are Provided in Terms of Value (USD).
Natural candidates also benefit from EU circular-economy incentives, accelerating collagen extraction from sardine scales and upcycling crustacean waste. Metallic biomaterials, though vulnerable to tantalum-and-niobium supply risks, remain indispensable in hip prostheses demanding high fatigue resistance. The biomaterials market continues to reward suppliers able to hedge raw-material volatility through recycling and dual-sourcing strategies.
Europe grapples with MDR bottlenecks - only 4,873 certificates were issued from 14,539 applications in 2023 - delaying launches and prompting some manufacturers to withdraw legacy devices. Despite this, Germany expects knee-replacement incidence to climb 55% by 2040, guaranteeing demand once compliance hurdles ease. EU circular-bioeconomy grants also fast-track insect-derived chitosan plants, giving natural materials an early-mover edge.
Asia-Pacific charts the fastest 15.03% CAGR, propelled by China’s fivefold jump in knee replacements and Japan’s first-in-human iPSC corneal transplants. Even with venture funding down 22% from 2021 highs, the region’s medtech sector still targets USD 225 billion in 2030 revenue, encouraging global OEMs to localize manufacturing. South Korea and Australia add capacity through advanced composite printing hubs, while India’s growing middle class amplifies volume demand for cost-efficient implants.
Global Biomaterials Market Trends and Insights
Aging population-led surge in joint-replacement volumes
Primary knee arthroplasty volumes in the United States alone are projected to climb 673% by 2030, and Germany anticipates a 55% rise in knee arthroplasties by 2040. Younger and more active patients now represent a majority of candidates, forcing implant developers to prioritize wear resistance and osseointegration longevity. Colombia projects 39,270 lower-limb arthroplasties by 2050, 52.7% of which will involve women, spurring gender-specific biomaterial formulations. The sustained procedure pipeline cushions the biomaterials market against traditional healthcare spending cycles.Rapid advances in regenerative medicine & 3-D bioprinting
The Canadian government’s CAD 72.75 million grant to Aspect Biosystems signals policy confidence in bioprinted tissues, while machine-learning-driven modelling achieves R² > 0.999 for shape predictions in 4D scaffolds. FDA clearance of Symvess, the first acellular tissue-engineered vessel, establishes precedent and accelerates clinical translation. As regulatory clarity improves, venture activity spreads to Asia-Pacific, where Japan’s iPSC-based corneal epithelial transplants underscore regional competitiveness, further strengthening the biomaterials market outlook.High production & surgical costs of next-gen biomaterials
Inflation and supply chain shocks inflated contract manufacturing costs during 2024, while polytetrafluoroethylene shortages forced insourcing and inventory stockpiling, impairing cash flow for small device makers. Tantalum prices climbed to USD 5,190 per kg in 2023, tightening margins for specialty implant suppliers. EU MDR compliance adds 18-24 months and significant certification costs, prompting 50% of surveyed European firms to trim portfolios.Other drivers and restraints analyzed in the detailed report include:
- Expansion of cardiovascular interventions using bio-stents
- Government R&D grants and fast-track approvals for breakthrough implants
- Lengthy multi-phase regulatory & clinical validation timelines
Segment Analysis
Polymeric materials retained a 39.62% share of the biomaterials market in 2025, dominating cardiovascular and orthopedic uses. Fish-waste collagen and insect-derived chitosan speed n atural-material uptake, driving a 14.52% CAGR that challenges polymeric supremacy. Composite hybrids marry metallic strength with polymeric elasticity, meeting load-bearing preferences in younger arthroplasty patients. Shape-memory polymers produced via 4D printing enable scaffolds that conform in vivo, a differentiator for tissue-engineering firms seeking reimbursement premiums.Natural candidates also benefit from EU circular-economy incentives, accelerating collagen extraction from sardine scales and upcycling crustacean waste. Metallic biomaterials, though vulnerable to tantalum-and-niobium supply risks, remain indispensable in hip prostheses demanding high fatigue resistance. The biomaterials market continues to reward suppliers able to hedge raw-material volatility through recycling and dual-sourcing strategies.
Complete Report Scope:
- By Material Type
- Metals
- Polymeric
- Ceramic
- Composite
- Natural
- By Origin
- Synthetic
- Natural
- By Application
- Orthopedic
- Cardiovascular
- Dental
- Wound Healing
- Neurology
- Plastic Surgery
- Tissue Engineering & Regeneration
- Others
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- North America
Geography Analysis
North America held 41.78% of biomaterials market share in 2025, buoyed by 1,041 FDA breakthrough designations and heavy corporate R&D. Established reimbursement and robust surgeon training programs encourage rapid adoption of premium implants signals federal backing for bioprinting ventures.Europe grapples with MDR bottlenecks - only 4,873 certificates were issued from 14,539 applications in 2023 - delaying launches and prompting some manufacturers to withdraw legacy devices. Despite this, Germany expects knee-replacement incidence to climb 55% by 2040, guaranteeing demand once compliance hurdles ease. EU circular-bioeconomy grants also fast-track insect-derived chitosan plants, giving natural materials an early-mover edge.
Asia-Pacific charts the fastest 15.03% CAGR, propelled by China’s fivefold jump in knee replacements and Japan’s first-in-human iPSC corneal transplants. Even with venture funding down 22% from 2021 highs, the region’s medtech sector still targets USD 225 billion in 2030 revenue, encouraging global OEMs to localize manufacturing. South Korea and Australia add capacity through advanced composite printing hubs, while India’s growing middle class amplifies volume demand for cost-efficient implants.
List of Companies Covered in this Report:
- Johnson & Johnson
- Stryker
- Medtronic
- Evonik Industries
- Corbion NV (Purac)
- Zimmer Biomet
- Covestro
- BASF
- Celanese Corporation
- Invibio (Victrex plc)
- DSM Biomedical
- Berkeley Advanced Biomaterials
- Dentsply Sirona
- Carpenter Technology
- Collagen Solutions plc
- Straumann Group
- Organogenesis
- Precision Biomaterials Inc.
- Wright Medical (now Stryker)
- 3M Health Care
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, 2024-2030)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Johnson & Johnson (DePuy Synthes)
- Stryker Corporation
- Medtronic plc
- Evonik Industries AG
- Corbion NV (Purac)
- Zimmer Biomet Holdings Inc.
- Covestro AG
- BASF SE
- Celanese Corporation
- Invibio (Victrex plc)
- DSM Biomedical
- Berkeley Advanced Biomaterials
- Dentsply Sirona
- Carpenter Technology Corporation
- Collagen Solutions plc
- Straumann Holding AG
- Organogenesis Inc.
- Precision Biomaterials Inc.
- Wright Medical (now Stryker)
- 3M Health Care
